Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H27N3O2 |
Molecular Weight | 329.4366 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(N1CCN(CC1)C2CC2)C3=CC=C(CN4CCOCC4)C=C3
InChI
InChIKey=BGBVSGSIXIIREO-UHFFFAOYSA-N
InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
Molecular Formula | C19H27N3O2 |
Molecular Weight | 329.4366 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22519922
Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methylphenidate hydrochloride 54 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 17:57:23 UTC 2022
by
admin
on
Sun Dec 18 17:57:23 UTC 2022
|
Record UNII |
9827P7LFVH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16061509
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
XX-116
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
CHEMBL2103862
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
9827P7LFVH
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
DTXSID001026045
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
C171762
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
DB12299
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
929622-08-2
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY | |||
|
9244
Created by
admin on Sun Dec 18 17:57:24 UTC 2022 , Edited by admin on Sun Dec 18 17:57:24 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |